论文部分内容阅读
目的:监测癫痫患者苯妥因钠(PHT)血药浓度,为临床安全、有效、合理地使用PHT提供理论依据。方法:采用荧光偏振免疫法测定癫痫患者PHT血药浓度,并结合临床疗效进行分析。结果:118例癫痫患者PHT血药浓度,低于10mg·mL-1有20例(17.0%),无效14例(70.0%);10～20mg·mL-172例(61.0%),无效8例(11.1%),中毒病例2例(2.8%);高于20mg·mL-1有26例(22.0%),无效2例(7.7%),中毒病例6例(23.1%)。结论:癫痫患者PHT血药浓度受年龄、肝功能、药物相互作用等因素的影响,常规开展血药浓度的监测,对于临床使用PHT治疗癫痫时确保疗效、减少毒性反应的发生,具有十分重要的作用。
Objective: To monitor the plasma concentration of phenytoin sodium (PHT) in patients with epilepsy and provide a theoretical basis for the safe, effective and rational use of PHT. Methods: Fluorescence polarization immunoassay was used to measure the plasma concentration of PHT in patients with epilepsy, and the clinical efficacy was analyzed. Results: The plasma concentrations of PHT in 118 epilepsy patients were 20 (17.0%) less than 10 mg · mL-1, 14 (70.0%) were ineffective, 10 to 20 mg · mL-172 (61.0% (11.1%), 2 cases (2.8%) were poisoned, 26 cases (22.0%) were higher than 20mg · mL-1, 2 cases were inactive (7.7%) and 6 cases were poisoned (23.1%). Conclusion: The blood concentration of PHT in patients with epilepsy is affected by factors such as age, liver function, drug interactions and so on. It is very important for routine monitoring of blood concentration to ensure efficacy and reduce the occurrence of toxic reactions in the clinical use of PHT in the treatment of epilepsy effect.